Literature DB >> 11192841

Systematic, combined treatment approach to nasolacrimal duct obstruction in different age groups.

F Ciftçi1, A Akman, M Sönmez, M Unal, A Güngör, V Yaylali.   

Abstract

PURPOSE: To report the outcome of a step-by-step treatment approach for congenital nasolacrimal duct obstruction (CNDO).
METHODS: Three-hundred and fifty eyes with CNDO were included in the study. A number of treatment methods were applied systematically until a successful outcome was achieved. Listed in order from simple to more complex, the following methods were used: conservative management (massage and topical antibiotics), high-pressure syringing, probing, and silicone intubation. Treatment efficacy was determined according to age (Group 1: 0-6 months, Group 2: 7-12 months, Group 3: 13-24 months, Group 4: 25-72 months) and success rates were compared.
RESULTS: Conservative management was applied only in children less than 1 year of age, and was successful in 91.8% of Group 1 and 60% of Group 2 eyes. The difference between these two success rates was significant (p = 0.003). High-pressure syringing was performed in children under 24 months of age, with success rates of 41.7% in Group 1, 33.3% in Group 2, and 12.5% in Group 3. The overall success rate for first probing in all groups was 76.1%, with a range of 69.4% to 80.9%. After second probing, the overall cure rate for the entire cohort was 88.0%, with a range of 74.9% to 94.8%. There was no real difference in probing cure rates relative to age (p > 0.05). Silicone intubation was indicated and performed in two eyes of Group 2 children, three eyes of Group 3, and nine eyes of Group 4. Two ducts in Group 4 eyes remained obstructed after silicone intubation.
CONCLUSIONS: The systematic treatment approach to CNDO, including conservative management and minimally invasive procedures such as high-pressure syringing, probing, and silicone intubation, is highly successful. In this study, the cure rate for this combined approach was 100% in youngsters under 2 years of age and 94.5% in children 2 to 6 years old.

Entities:  

Mesh:

Year:  2000        PMID: 11192841     DOI: 10.1177/112067210001000409

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   1.922


  6 in total

1.  [Increased prevalence of congenital dacryostenosis following cesarean section].

Authors:  Claudia Kuhli-Hattenbach; M Lüchtenberg; C Hofmann; T Kohnen
Journal:  Ophthalmologe       Date:  2016-08       Impact factor: 1.059

2.  Probing for congenital nasolacrimal duct obstruction in older children.

Authors:  Bahram Eshragi; Masoud Aghsaei Fard; Babak Masomian; Mohammadreza Akbari
Journal:  Middle East Afr J Ophthalmol       Date:  2013 Oct-Dec

3.  Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years.

Authors:  Michael X Repka; Danielle L Chandler; Roy W Beck; Eric R Crouch; Sean Donahue; Jonathan M Holmes; Katherine Lee; Michele Melia; Graham E Quinn; Nick A Sala; Susan Schloff; David I Silbert; David K Wallace
Journal:  Ophthalmology       Date:  2007-11-08       Impact factor: 12.079

4.  Primary treatment of nasolacrimal duct obstruction with nasolacrimal duct intubation in children younger than 4 years of age.

Authors:  Michael X Repka; B Michele Melia; Roy W Beck; C Scott Atkinson; Danielle L Chandler; Jonathan M Holmes; Alexander Khammar; David Morrison; Graham E Quinn; David I Silbert; Benjamin H Ticho; David K Wallace; David R Weakley
Journal:  J AAPOS       Date:  2008-07-02       Impact factor: 1.220

5.  Balloon catheter dilation and nasolacrimal duct intubation for treatment of nasolacrimal duct obstruction after failed probing.

Authors:  Michael X Repka; Danielle L Chandler; Jonathan M Holmes; Darren L Hoover; Christine L Morse; Susan Schloff; David I Silbert; D Robbins Tien
Journal:  Arch Ophthalmol       Date:  2009-05

6.  Late and very late initial probing for congenital nasolacrimal duct obstruction: what is the cause of failure?

Authors:  M B Kashkouli; B Beigi; M M Parvaresh; A Kassaee; Z Tabatabaee
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.